In continuation to the disclosure made in the prospectus of the initial public offering (Pg. No. 198 – ‘Facilities and Approvals’) and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’) Sai Life Sciences has informed that the Company has successfully opened Unit VI, a dedicated facility for veterinary API production, in Bidar, India, located alongside Unit IV, the company’s flagship API manufacturing site in Bidar, Karnataka, India (‘Unit IV Bidar Facility’) on 18th September 2025. The new facility is designed to meet the highest standards of safety, sustainability, and regulatory compliance, ensuring the production of high-quality APIs for veterinary applications. With this expansion, the Company aims to provide efficient and scalable manufacturing solutions to leading global animal health companies.
The above information is a part of company’s filings submitted to BSE.
